We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.
- Authors
Ma, Tiantian; Shi, Jing; Liu, Huasheng
- Abstract
Multiple myeloma (MM) remains an incurable plasma cells malignancy because of its complex genetic heterogeneity and high relapse rate post immunotherapy. The encouraging results of chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen (BCMA) immunotherapy clinical trials have shed light on curing MM in recent years. However, many therapeutic side effects limit the promotion and clinical use of this novel effective approach such as cytokine release syndrome, antigen escape, and neurotoxicity. We should make every effort to do further study about this immunotherapy to make it safer and effective. This review focusing on this topic clarifies the following contents: present status of MM treatment, effectiveness of CAR-T cells, features of BCMA, preclinical and clinical trials of BCMA CAR-T cells therapy, and existing problems and strategies. Hoping to provide a reference for the subsequent correlative clinical and research.
- Subjects
CHIMERIC antigen receptors; B cells; MULTIPLE myeloma treatment; CELL receptors; IMMUNIZATION; MULTIPLE myeloma; PROTEINS; RESEARCH funding; T cells; TRANSPLANTATION of organs, tissues, etc.
- Publication
Annals of Hematology, 2019, Vol 98, Issue 4, p813
- ISSN
0939-5555
- Publication type
journal article
- DOI
10.1007/s00277-018-03592-9